Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Feb 12;144(1):14-17.
doi: 10.1093/brain/awaa422.

Concatenating plasma p-tau to Alzheimer's disease

Betty M Tijms  1 , Charlotte E Teunissen  2
Affiliations
Comment

Concatenating plasma p-tau to Alzheimer's disease

Betty M Tijms et al. Brain. .

Abstract

This scientific commentary refers to ‘Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum’, by Moscoso et al. (doi:10.1093/brain/awaa399).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect size forest plots of reported relationships between plasma p-tau 181 and other biomarkers for amyloid and tau, for total group (left), abnormal amyloid (middle), and normal amyloid (right). (A) Correlations with amyloid PET; (B) correlations with tau PET [note, in Moscoso et al. (2021), tau PET was acquired 6 years after the plasma p-tau measures]; and (C) correlations with CSF p-tau 181. Figure created with the R package ‘meta’ version 4.15-1.
See this image and copyright information in PMC

Comment on

References

    1. Budgeon CA, Murray K, Turlach BA, Baker S, Villemagne VL, Burnham SC, et al. Constructing longitudinal disease progression curves using sparse, short-term individual data with an application to Alzheimer's disease. Stat Med 2017; 36: 2720–34. - PubMed
    1. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dementia 2018; 14: 535–62. - PMC - PubMed
    1. Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med 2020; 26: 379–86. - PubMed
    1. Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 2020; 19: 422–33. - PubMed
    1. Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dementia 2018; 14: 989–97. - PMC - PubMed